home / lobbying / lobbying_activities

lobbying_activities: 1077430

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id filing_uuid filing_type registrant_name registrant_id client_name filing_year filing_period issue_code specific_issues government_entities income_amount expense_amount is_no_activity is_termination received_date
1077430 7105b1a3-761e-4e04-ac2b-684601fedec3 Q1 AARP 1694 AARP 2011 first_quarter PHA H.J. Res. 44, H.J. 48, Continuing Appropriations Amendments, FY 2011 - Lobbied for funding for FDA Office of Generic Drugs and nutrition assistance. Discussed legislative intent with respect to Biologic drugs and exclusivity period.(no bill) S. 319, Pharmaceutical Market Access and Drug Safety Act of 2011 - Discussed importance of potential savings to consumers through safe importation of prescription drugs and endorsed legislation. Discussed importance of potential savings both to consumers and to the federal government of granting Secretarial Negotiating Authority to Secretary of HHS on Medicare Part D. (no bill) Discussed need for greater consumer safety protections both in OTC and prescription drugs. (no bill) Discussed need to end industry tactics like Pay for Delay which inappropriately extends patents with effect of keeping prices high for consumers and government. (no bill) Discussed need for doctors to get unbiased information on prescription pharmaceuticals through programs like academic detailing. (no bill) Discussed possible savings and better health care outcomes that could result from Medication Therapy Management. (no bill) Pub. Law 111-148 and 111-152 - Discussed implementation of health care legislation to reform the health care system to provide quality healthcare, expand access to long-term services and supports, and reduced prescription drug costs. Discussed greater affordability of generic versions of both generic and biologic drugs. Administration on Aging,Agriculture, Dept of (USDA),Bureau of the Census,Centers For Medicare and Medicaid Services (CMS),Energy, Dept of,Equal Employment Opportunity Commission (EEOC),Federal Communications Commission (FCC),Federal Energy Regulatory Commission (FERC),Federal Reserve System,Federal Transit Administration (FTA),Food & Drug Administration (FDA),Government Accountability Office (GAO),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Housing & Urban Development, Dept of (HUD),Internal Revenue Service (IRS),Justice, Dept of (DOJ),Labor, Dept of (DOL),Medicare Payment Advisory Commission (MedPAC),Natl Highway Traffic Safety Administration (NHTSA),Office of Management & Budget (OMB),Office of Personnel Management (OPM),Securities & Exchange Commission (SEC),SENATE,Social Security Administration (SSA),Transportation, Dept of (DOT),Treasury, Dept of,White House Office   5000000 0 0 2011-04-15T14:49:02.477000-04:00
Powered by Datasette · Queries took 0.978ms · Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API